{
    "organizations": [],
    "uuid": "21afd5cb8473b298aecead3e9124b5769b96a051",
    "author": "",
    "url": "https://www.reuters.com/article/brief-apellis-pharmaceuticals-provides-u/brief-apellis-pharmaceuticals-provides-update-on-phase-1b-open-label-study-of-apl-2-in-pnh-patients-not-previously-treated-with-eculizumab-idUSASC09VYA",
    "ord_in_thread": 0,
    "title": "BRIEF-Apellis Pharmaceuticals Provides Update On Phase 1B Open Label Study Of APL-2 In Pnh Patients Not Previously Treated With Eculizumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News April 16, 2018 / 1:36 PM / Updated 7 minutes ago BRIEF-Apellis Pharmaceuticals Provides Update On Phase 1B Open Label Study Of APL-2 In Pnh Patients Not Previously Treated With Eculizumab Reuters Staff 1 Min Read \nApril 16 (Reuters) - Apellis Pharmaceuticals Inc: \n* APELLIS PHARMACEUTICALS PROVIDES UPDATE ON PHASE 1B OPEN LABEL STUDY OF APL-2 IN PNH PATIENTS NOT PREVIOUSLY TREATED WITH ECULIZUMAB \n* APELLIS PHARMACEUTICALS INC - TO DATE, APL-2 HAS GENERALLY BEEN WELL-TOLERATED IN PATIENTS \n* APELLIS PHARMACEUTICALS INC - EXPECTS TO REPORTING FURTHER UPDATES TO ONGOING PADDOCK TRIAL IN JUNE \n* APELLIS - IN H2 2018, PLANS TO INITIATE A PHASE 3 TRIAL IN 70 PATIENTS WITH PNH VERSUS TREATMENT WITH APL-2 MONOTHERAPY TO TREATMENT WITH ECULIZUMAB Source text for Eikon: Further company coverage:",
    "published": "2018-04-16T16:35:00.000+03:00",
    "crawled": "2018-04-16T16:53:20.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "provides",
        "update",
        "phase",
        "1b",
        "open",
        "label",
        "study",
        "pnh",
        "patient",
        "previously",
        "treated",
        "eculizumab",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "apellis",
        "pharmaceutical",
        "inc",
        "apellis",
        "pharmaceutical",
        "provides",
        "update",
        "phase",
        "1b",
        "open",
        "label",
        "study",
        "pnh",
        "patient",
        "previously",
        "treated",
        "eculizumab",
        "apellis",
        "pharmaceutical",
        "inc",
        "date",
        "generally",
        "patient",
        "apellis",
        "pharmaceutical",
        "inc",
        "expects",
        "reporting",
        "update",
        "ongoing",
        "paddock",
        "trial",
        "june",
        "apellis",
        "h2",
        "plan",
        "initiate",
        "phase",
        "trial",
        "patient",
        "pnh",
        "versus",
        "treatment",
        "monotherapy",
        "treatment",
        "eculizumab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}